ReviewAdvanced drug delivery reviews2011
Using drug-excipient interactions for siRNA delivery.
Review in Advanced drug delivery reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Safety and Pharmacokinetics of SRN001, a Novel siRNA Drug Targeting Amphiregulin via the SAMiRNA Platform.Drug design, development and therapy · 2026Trial
- Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases.International journal of nanomedicine · 2026Review
- Article
- Article
- Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.International journal of molecular sciences · 2024Review
- An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics.Pharmaceutics · 2023Review
- Effect of the array of amines on the transfection efficiency of cationic peptidomimetic lipid molecules into neural cells.RSC advances · 2022Article
- Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.Pharmaceutical research · 2020Article
- Construction and Biological Evaluation of a Novel Integrin αMolecules (Basel, Switzerland) · 2017Article
- Polysaccharide Nanoparticles for Efficient siRNA Targeting in Cancer Cells by Supramolecular pKa Shift.Scientific reports · 2016Article
- Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes.Future science OA · 2015Article
- Article
- RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry.ACS nano · 2014Article
- The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.Molecular pharmaceutics · 2014Article
- Phospholipid-modified polyethylenimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid components.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Redox-based control of the transformation and activation of siRNA complexes in extracellular environments using ferrocenyl lipids.Journal of the American Chemical Society · 2013Article
- A microfluidic chip using phenol formaldehyde resin for uniform-sized polycaprolactone and chitosan microparticle generation.Molecules (Basel, Switzerland) · 2013Article
- Polymeric nucleic acid carriers: current issues and novel design approaches.Journal of controlled release : official journal of the Controlled Release Society · 2012Review
- Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SiRNA is the trigger of RNA interference, a mechanism discovered in the late 1990s. To release the therapeutic potential of this versatile but large and fragile molecule, excipients are used which either interact by electrostatic interaction, passively encapsulate siRNA or are covalently attached to enable specific and safe delivery of the drug substance. Controlling the delicate balance between protective complexation and release of siRNA at the right point and time is done by understanding excipients-siRNA interactions. These can be lipids, polymers such as PEI, PLGA, Chitosans, Cyclodextrins, as well as aptamers and peptides. This review describes the mechanisms of interaction of the most commonly used siRNA delivery vehicles, and looks at the results of their clinical and preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.